Vaccine News: Cineplex Gets Its House in Order While We Wait for a Vaccine

Cineplex stock is set to rally hard when the coronavirus vaccine is developed, right now it is biding its time focusing on survival.

| More on:
analyze data

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Vaccine news out of Pfizer this week was extremely encouraging. And the hopeful message was not lost on Cineplex stock, which has rallied 24% higher in the last week. Cineplex released its third-quarter 2020 earnings results today. Here are three takeaways from its earnings call.

Cineplex stock: a company in waiting – for the vaccine and for the return of moviegoers

The vaccine news out of Pfizer this week was a definite boost to Cineplex stock. For a company that has focused on surviving the crisis, a glimpse of the possible way out has been very encouraging.

My main focus with respect to Cineplex is this: “How does the company manage those variables that are under its control?” Because no company can control external, macro events. But those companies that handle what they can control will always be the survivors.

Cineplex is one of those companies that handles itself well. From the threat of streaming services, to the coronavirus pandemic today, Cineplex has always handled itself well, regardless of the struggles it is facing.

Cineplex focuses on cost control and liquidity

The coronavirus pandemic has shattered the movie exhibition business. Outright closures followed by capacity restrictions and a lack of film product has hit Cineplex hard. Today, the focus is on cost control and liquidity. Cineplex is aiming to survive this unprecedented time so that when a vaccine comes, it will be there to reap the rewards.

Lease costs are Cineplex’s single largest fixed cost. Abatements and conversions from fixed to variable leasing arrangements have helped Cineplex lessen the blow. So far, lease costs have been reduced by $58 million, with more savings expected in Q4 and 2021.

Cineplex’s largest semi-fixed cost is payroll. Cineplex has received $22 million in government subsidies and has reduced its payroll to $3.9 million from $78 million. These are big savings that are allowing Cineplex to survive this crisis and come out on the other side. And once a vaccine is well established in the population, Cineplex will do just that.

So what awaits Cineplex when this vaccine is available and things go back to normal? Well, on Cineplex’s third quarter earnings call, management highlighted the Japanese experience. Since the Japanese government recently eased restrictions, movie theatres there have been booming. And surveys here in Canada show that those who returned to the theatres after they reopened in August were highly satisfied.

Cineplex is biding its time by focusing on its other business segments

Cineplex’s other business segments, such as food delivery service, digital media, and Cineplex Store, are thriving. Although they are a small part of Cineplex’s overall business, it is at least something. Cineplex Store, for example, has seen a 41% increase in its customer base, with over two million transactions in the quarter.

So with management increasing its focus on these areas, we can look forward to seeing more progress here to lessen the blow of the movie exhibition business, even if it is only a marginal impact.

Motley Fool: the bottom line

When a coronavirus vaccine comes to the market, Cineplex stock will break out big. The company has worked on securing itself financially to ride out the storm. A large list of blockbuster theatrical releases, as well as excited movie goers will make the return of the movie theatres a hugely profitable time for Cineplex.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karen Thomas has no position in any of the stocks mentioned.

More on Coronavirus

little girl in pilot costume playing and dreaming of flying over the sky
Coronavirus

Air Canada Stock: How High Could it go?

AC stock is up 29% in the last six months alone, so should we expect more great things? Or is…

Read more »

eat food
Coronavirus

Goodfood Stock Doubles Within Days: Time to Buy?

Goodfood (TSX:FOOD) stock has surged 125% in the last few weeks, so what happened, and should investors hop back on…

Read more »

stock data
Tech Stocks

If I Could Only Buy 1 Stock Before 2023, This Would Be It

This stock is the one company that really doesn't deserve its ultra-low share price, so I'll definitely pick it up…

Read more »

Aircraft Mechanic checking jet engine of the airplane
Coronavirus

Air Canada Stock Fell 5% in November: Is it a Buy Today?

Air Canada (TSX:AC) stock saw remarkable improvements during its last quarter but still dropped 5% with more recession hints. So,…

Read more »

Airport and plane
Coronavirus

Is Air Canada Stock a Buy Today?

Airlines are on the rebound. Does Air Canada stock deserve to be on your buy list?

Read more »

A patient takes medicine out of a daily pill box.
Coronavirus

Retirees: 2 Healthcare Stocks That Could Help Set You up for Life

Healthcare stocks offer an incredible opportunity for growth for those investors who look to the right stocks, such as these…

Read more »

sad concerned deep in thought
Coronavirus

Here’s Why I Just Bought WELL Health Stock

WELL Health stock (TSX:WELL) may be a healthcare stock and a tech stock, but don't let that keep you from…

Read more »

healthcare pharma
Coronavirus

WELL Stock: The Safe Stock Investors Can’t Afford to Ignore

WELL stock (TSX:WELL) fell 68% from peak to trough, and yet there's no good reason as to why. So now…

Read more »